[en] OBJECTIVE: To identify biological evidence for Alzheimer disease (AD) in individuals with subjective memory impairment (SMI) and unimpaired cognitive performance and to investigate the longitudinal cognitive course in these subjects.
METHOD: [¹⁸F]fluoro-2-deoxyglucose PET (FDG-PET) and structural MRI were acquired in 31 subjects with SMI and 56 controls. Cognitive follow-up testing was performed (average follow-up time: 35 months). Differences in baseline brain imaging data and in memory decline were assessed between both groups. Associations of memory decline with brain imaging data were tested.
RESULTS: The SMI group showed hypometabolism in the right precuneus and hypermetabolism in the right medial temporal lobe. Gray matter volume was reduced in the right hippocampus in the SMI group. At follow-up, subjects with SMI showed a poorer performance than controls on measures of episodic memory. Longitudinal memory decline in the SMI group was associated with reduced glucose metabolism in the right precuneus at baseline.
CONCLUSION: The cross-sectional difference in 2 independent neuroimaging modalities indicates early AD pathology in SMI. The poorer memory performance at follow-up and the association of reduced longitudinal memory performance with hypometabolism in the precuneus at baseline support the concept of SMI as the earliest manifestation of AD.
Disciplines :
Neurology
Author, co-author :
Scheef, Lukas; Department of Radiology, University of Bonn, Bonn, Germany
Spottke, Annika; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
Daerr, Moritz; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
Joe, Alexius; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
Striepens, Nadine; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
Kölsch, Heike; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
Popp, Julius; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
Daamen, Marcel; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
Gorris, Dominik; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
HENEKA, Michael ; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
Boecker, Henning; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
Biersack, Hans J; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
Maier, Wolfgang; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
Schild, Hans H; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
Wagner, Michael; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
Jessen, Frank; From the Departments of Radiology (L.S., M. Daamen, H.B., H.H.S.), Psychiatry (A.S., M. Daerr, N.S., H.K., J.P., D.G., W.M., M.W., F.J.), Neurology (A.S., M.T.H.), and Nuclear Medicine (A.J., H.J.B.), and Clinical Neuroscience Unit, Department of Neurology (M.T.H.), University of Bonn, Bonn, German Center for Neurodegenerative Diseases (DZNE) (A.S., M.T.H., H.B., W.M., M.W., F.J.), Bonn, Germany, and Department of Psychiatry (J.P.), University Hospital of Lausanne, Switzerland.
L. Scheef, A. Spottke, M. Daerr, A. Joe, N. Striepens, H. Kölsch, J. Popp, M. Daamen, D. Gorris, M.T. Heneka, and H. Boecker report no disclosures. H.J. Biersack has received speaker honoraria and grants from Sirtex and Nordion. Wolfgang Maier has received consultation fees and speaker honoraria from AstraZeneca, Boehringer-Ingelheim, Lilly, Lundbeck, Merz, and Pfizer. H.H. Schild and M. Wagner report no disclosures, F. Jessen has received consultation fees and speaker honoraria from Pfizer, Eisai, Novartis, Janssen-Cilag, GE Healthcare, Lilly, AC Immune, and Schwabe. Go to Neurology.org for full disclosures.
Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment: beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-246.
Jack CR Jr., Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.
Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385-393.
Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-279.
Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118-1127.
Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising theNINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-746.
Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry 2000; 15:983-991.
Reid LM, Maclullich AM. Subjective memory complaints and cognitive impairment in older people. Dement Geriatr Cogn Disord 2006;22:471- 485.
Reisberg B, Shulman MB, Torossian C, Leng L, Zhu W. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement 2010;6:11-24.
Jessen F, Wiese B, Bachmann C, et al. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry 2010;67:414-422.
Chetelat G, Villemagne VL, Pike KE, et al. Larger temporal volume in elderly with high versus low beta-Amyloid deposition. Brain 2010;133:3349-3358.
Jessen F, Feyen L, Freymann K, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging 2006;27:1751-1756.
Saykin AJ, Wishart HA, Rabin LA, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology 2006;67:834-842.
Mosconi L, De Santi S, Brys M, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 2008;63:609-618.
Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009;8:619- 627.
Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31: 1275-1283.
Erk S, Spottke A, Meisen A, Wagner M, Walter H, Jessen F. Evidence for neuronal compensation during episodic memory in subjective memory impairment. Arch Gen Psychiatry 2011;68:845- 852.
Carr DB, Gray S, Baty J, Morris JC. The value of informant versus individual's complaints of memory impairment in early dementia. Neurology 2000;55:1724-1726.
Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part I: clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39: 1159-1165.
Chandler MJ, Lacritz LH, Hynan LS, et al. A total score for the CERAD neuropsychological battery. Neurology 2005;65:102-106.
Wittchen HU, Zaudig M, Fydrich T. Strukturiertes Klinisches Interview fur DSM-IV (SKID). Gottingen: Hogrefe; 1997.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
Muller H, Hasse-Sander I, Horn R, Helmstaedter C, Elger CE. Rey Auditory-Verbal Learning Test: structure of a modified German version. J Clin Psychol 1997;53:663-671.
Osterrieth PA. Le test de copie d'une figure complexe: contribution a l'etude de la perception et de la memoire [The test of copying a complex figure: a contribution to the study of perception and memory]. Arch Psychol 1944;30:70.
Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003;19:1233-1239.
Ashburner J. A fast diffeomorphic image registration algorithm. NeuroImage 2007;38:95-113.
Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuro- Image 2001;14:21-36.
Striepens N, Scheef L, Wind A, et al. Interaction effects of subjective memory impairment and ApoE4 genotype on episodic memory and hippocampal volume. Psychol Med 2011;41:1-10.
Striepens N, Scheef L, Wind A, et al. Volume loss of the medial temporal lobe structures in subjective memory impairment. Dement Geriatr Cogn Disord 2010;29:75- 81.
Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560-574.
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000;343:450-456.
Mondadori CR, Buchmann A, Mustovic H, et al. Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years. Brain 2006;129:2908-2922.
Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 2008;7:436-450.
Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 2008;64:492- 498.
Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet 2006;367:1262-1270.
Jessen F, Wiese B, Cvetanovska G, et al. Patterns of subjective memory impairment in the elderly: association with memory performance. Psychol Med 2007;37:1753-1762.
